Biogen Inc.
04/06/2026 | Press release | Distributed by Public on 04/06/2026 04:32
Business/Financial Results (Form 8-K)
Item 2.02 Results of Operations and Financial Condition
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share.
Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development. Biogen does not forecast such acquired in-process research and development, upfront and milestone expense due to the uncertainty of the future occurrence, magnitude and timing of these transactions in any given period.
Results for the quarter ended March 31, 2026, have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from the preliminary unaudited estimates described herein.
Biogen Inc. published this content on April 06, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 06, 2026 at 10:32 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]